Language:
Daily summary of financings for therapeutic biotechnology company executives and investors
Thursday, September 17, 2026
Lisata Therapeutics’ $225 Million Concurrent Private Placement
North Immunology’s $180 Million Oversubscribed Concurrent Private Placement
Matisse Pharmaceuticals’ $16 Million Series A
Wednesday, September 16, 2026
Sling Therapeutics’ $123 Million Series C
Tuesday, September 15, 2026
RegCell’s $44 Million Series A
Clene’s $4 Million Registered Direct Offering
Monday, September 14, 2026
Tyra’s $400 Million Public Offering
Shennon’s $12 Million Financing
Thursday, September 10, 2026
Yarrow’s $150 Million Public Offering
Wednesday, September 9, 2026
Encoded Therapeutics’ $275 Million Series F
Solstice Oncology’s $225 Million Series A
Tectora’s $55 Million Series A
Caspian Therapeutics’ $50 Million Financing
NeOnc’s $15 Million Registered Direct Offering
Cytonics’ $4.8 Million Financing
Allogenetics’ $4.3 Million Pre-Series A
ARTCLINE’s $3.9 Million Financing
Tuesday, September 8, 2026
Korsana’s $380 Million Private Placement
BrainChild Bio’s $116 Million Series A
Moonwalk’s $70 Million Series B
Cloverleaf’s $33 Million Seed Financing
Thursday, September 3, 2026
NeuShen Therapeutics’ $80 Million Series B
Superluminal’s $60 Million Series B
Wednesday, September 2, 2026
Typewriter’s $56 Million Series A
N-Power Medicine’s $32 Million Series B
Modus Therapeutics’ $773 Thousand Directed Issue
Tuesday, September 1, 2026
CytoDyn’s $17 Million Venture Financing
Amyl’s $9 Million Series A Extension
Monday, August 31, 2026
PMV Pharma’s $50.8 Million Public Offering
Kazia Therapeutics’ $40 Million Public Offering
EIT Pharma’s $35 Million Series A
Securities are offered through Finalis Securities LLC Member FINRA / SIPC. Collabrity is not a registered broker-dealer, and Finalis Securities LLC and Collabrity are separate, unaffiliated entities. Finalis Securities LLC, Office of Supervisory Jurisdiction is located at 450 Lexington Ave, New York, NY 10017, 800-962-0418.
Finalis Privacy Policy | Finalis Business Continuity Plan | FINRA BrokerCheck | Finalis Form Customer Relationship Summary (“Form CRS”)
collabrityreport.com (the “Collabrity Report Website”) is a website operated by Collabrity. This website is for informational purposes only, is not an offer, solicitation, recommendation, or commitment for any transaction or to buy or sell any security or other financial product, and is not intended as investment advice or as a confirmation of any transaction. Products and services on this website may not be available for residents of certain jurisdictions. Please consult with a Finalis Securities’ registered representative regarding the product or service in question for further information. Investments involve risk and are not guaranteed to appreciate. Any market price, indicative value, estimate, view, opinion, data, or other information herein is not warranted as to completeness or accuracy, is subject to change without notice, and Collabrity along with Finalis Securities LLC accepts no liability for its use or to update it or keep it current.
Investing in private placements involves a high degree of risk. These investments may be illiquid, speculative, and subject to substantial restrictions on transferability. Investors may lose all or part of their investment and should only invest capital they can afford to lose. Prospective investors should conduct their own due diligence and consult with their legal, tax, and financial advisors prior to making any investment decision. For your reference, Finalis’ Form CRS describes the services that we provide, how we are compensated, and other important information about Finalis Securities LLC.